Fate Therapeutics (FATE) Cash from Financing Activities (2012 - 2025)

Fate Therapeutics has reported Cash from Financing Activities for 14 years, with the latest figure at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 46.01% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $5.5 million (down 94.5% YoY), and the FY2025 full-year result was $5.5 million, down 94.5% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $1.7 million, down from $2.5 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $438.0 million in Q1 2021, with the low at -$180000.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $33.4 million across 5 years, with a median of $2.5 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 111.87% — and 2024, when it surged 46029.47%.
• Fate Therapeutics' Cash from Financing Activities stood at $3.4 million in 2021, then plunged by 55.62% to $1.5 million in 2022, then slumped by 111.87% to -$180000.0 in 2023, then jumped by 1838.89% to $3.1 million in 2024, then tumbled by 46.01% to $1.7 million in 2025.
• The last three Cash from Financing Activities figures came in at $1.7 million (Q4 2025), $2.5 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.